In tumor microenvironments, the macrophage population is heterogeneous, but some macrophages can acquire tumorpromoting characteristics. These tumor-associated macrophages (TAM) exhibit an M2-like profile, with deficient production of NO and ROS, characteristics of pro-inflammatory M1 cytotoxic macrophages. Lipoxins (LX) and 15-epi-lipoxins are lipid mediators which can induce certain features of M2 macrophages in mononuclear cells, but their effects on TAM remain to be elucidated. This study tested the hypothesis that ATL-1, a synthetic analogue of 15-epi-lipoxin A 4 , could modulate TAM activity profile. We show that human macrophages (MU) differentiated into TAM-like cells after incubation with conditioned medium from MV3, a human melanoma lineage cell. Contrasting with the effects observed in other M2 subsets and M1 profile macrophages, ATL-1 selectively decreased M2 surface markers in TAM, suggesting unique behavior of this particular M2 subset. Importantly, these results were replicated by the natural lipoxins LXA 4 and the aspirin induced 15-epi-LXA 4 (ATL). In parallel, ATL-1 stimulated TAM to produce NO by increasing the iNOS/arginase ratio and activated NADPH oxidase, triggering ROS production. These alterations in TAM profile induced by ATL-1 led to loss of the anti-apoptotic effects of TAM on melanoma cells and increased their cytotoxic properties. Finally, ATL-1 was found to inhibit tumor progression in a murine model in vivo, which was accompanied by alterations in TAM profile and diminished angiogenesis. Together, the results show an unexpected effect of lipoxin, which induces in TAM a change from an M2-to an M1-like profile, thereby triggering tumor cell apoptosis and down-modulating the tumor progression.
processes of tissue remodeling and angiogenesis. 1 An early event in tumor progression is the recruitment of monocytes to the tumor site, where they differentiate into macrophages (MU). 2, 3 These cells, as important effectors of the inflammatory response and its resolution, can provide an immediate defense against neoplastic elements but may promote tumor development through action at different stages. 4, 5 This paradoxical role of MU in cancer could be explained by their functional plasticity, which results in heterogeneous populations, some expressing pro-and others anti-tumoral functions. [5] [6] [7] During the acute inflammatory response, MU with an M1 profile acquire a potent cytotoxic profile, with increasing production of nitric oxide (NO) and reactive oxygen species (ROS), which mediate the elimination of pathogens or neoplastic cells. 8 However, evidence has shown that tumor cells can suppress these immune functions, primarily through down-regulation of this activity, allowing growth and spread of the cancer throughout the body, resulting in death of the host. 8, 9 Tumor cells create a microenvironment in which signals the acquisition of an M2-like profile. These MU, designated tumor-associated macrophages (TAM), possess protumor characteristics, and, in contrast to M1 MU, exhibit low cytotoxic properties with defective production of NO and ROS, which allow tumor progression. 10, 11 A number of studies have reported a positive correlation between high TAM density and poor prognosis in several human tumors. [12] [13] [14] The dual role of MU in both endogenous tumor defense and tumor progression suggests that a better understanding of the molecular and cellular mechanisms involved in macrophagetumor interactions is critical to developing new tools to control cancer progression. The balance between the different tumor-derived mediators may modulate the outcome of the M/ response and consequent tumor development. Lipoxins (LX) are specialized pro-resolving lipid mediators, produced by lipoxygenase interactions under a variety of conditions, including infection and inflammation. They can be produced by different biosynthetic routes in particular biological settings 15, 16 and can exert selective effects on monocytes and M/s in vitro and in vivo [17] [18] [19] [20] [21] with potential for control of tumor growth.
Although some studies reveal down-regulation of lipoxins in certain tumors, 22, 23 at present little is known about their effects on TAM behavior in the tumor microenvironment.
In this study, we investigated the role of lipoxins in the activity of TAM, using ATL-1 [15-epi-16 -(parafluoro)phenoxy-LXA 4 ], a more stable analog of 15-epi-lipoxinA 4 , an aspirin-inducible lipoxin. We show that this LXA 4 analog down-modulates the pro-tumor activity of TAM, inducing a shift from the M2 to the M1 cytotoxic profile, capable of promoting tumor cell apoptosis and controlling tumor growth in vivo. 
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cycle. For the induction of tumors, mice (n 5 6-8) were injected with B16F10 melanoma cells (2 3 10 5 cells/mouse suspended in 30 lL of saline) by the subcutaneous (s.c.) route. After 14 days, a group of mice were sacrificed and the tumor mass was removed. The other animals were injected intravenously with ATL-1 (1 lg/mouse) or with ethanol (Vehicle), 14 days after melanoma cell injection. For experimental analysis, these mice were sacrificed on Day 21 after melanoma induction and the tumor masses were removed for histological analysis, morphometry, immunohistochemistry and cellular profile analysis. Lung and liver were analyzed to detect metastasis.
Macrophage isolation and TAM differentiation
Isolated PBMCs were obtained from EDTA (0.5%)-treated venous blood of healthy volunteers by Ficoll-Hypaque density gradient, as described previously. 20 Cells were plated for 1 hr to isolate lymphocytes and monocytes were cultured for 7 days for MU maturation. To obtain TAM, the MU were cultured for an additional 3 days with RPMI 1640 medium plus conditioned medium from MV3 cultures (MV3-CM; 1:1), as described earlier.
Measurement of TAM survival
A modified MTT [3-(4,5-dimethylthiazol-2-yl)22,5-diphenyltetrazolium bromide] assay was used to quantify the effect of lipoxins on TAM survival. This method measures mitochondrial function as described previously. 20 Briefly, MU and TAM (2 3 10 5 cells/well) were incubated with or without ATL-1 (10-100 nM), LXA 4 (10 nm) and 15-epi-LXA 4 (10 nM) for 48 hr. Survival was assessed and expressed as % of live cells above the negative control.
FACS analysis
Fluorescence-activated cell sorting (FACS) analysis was conducted with an ACCURI C6 flow cytometer with CFLOW software (Becton Dickinson, Heidelberg, Germany). MU and TAM (1 3 10 6 cells/well) cultured in 24-well plates were treated with ATL-1 (1-100 nM), LXA 4 (10 nM) and 15-epi-LXA 4 (10 nM) for 48 hr. Following incubation, the cells were stained with conjugated monoclonal antibodies MRC1-phycoerythrin (PE), CD68-fluorescein (FITC) or CD86-PerCPCy5.5 (Biolegend) with which they were incubated for 60 min at RT in the presence of blocking solution (2% bovine serum albumin, 5% fetal bovine serum and 0.1% sodium azide). An isotype control antibody was used as the negative control.
RNA isolation and RT-PCR
MU and TAM (3 3 10 6 cells/well) were incubated with or without ATL-1 (10 nM) for 6 hr. Total RNA was isolated from TAM using RNeasy Mini kits (Quiagen V R , Hilden, Germany) . After DNase treatment (RQ1 RNase-Free DNase), the mRNA was reverse transcribed using high-capacity cDNA reverse transcription kits as described previously. 24 Primers were designed based on the sequence of human IL-10 (GeneBank accession n NM_000265 -IL-10: sense
. PCR was performed with the following program: 1 cycle of 958C for 5 min and 32 cycles of denaturation at 958C for 45 sec, annealing at 588C for 30 sec, and elongation at 728C for 30 sec. Primers were used to validate the cDNA in each reaction. PCR products were separated by 2% agarose gel electrophoresis and visualized by UV exposure on a transilluminator. Relative band densities were determined by densitometric analysis using National Institutes of Health Image Software, and the ratios calculated.
NO production
Nitrite release by TAM was determined by the accumulation of a stable nitrite end-product in cell-free culture supernatants using a modified Griess reaction method, as performed by Silva et al. 25 Briefly, TAM (2 3 10 6 cell/mL) were incubated with ATL-1 (1-100 nM) for 8 hr, and the samples incubated with the Griess reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% naphtylethylenodiamine). The nitrite concentration was then determined as previously described. 25 
ROS production assays
MU and TAM were suspended in Hanks balanced salt solution (HBSS) and placed in a white, 96-well plate (2 3 10 5 cells/well, final volume 200 mL). Following pretreatment with or without DPI (10 mM) or BOC-1 (10 mM) for 15 min, cells were loaded with Luminol (50 mM) and hydroxyphenylfluorescein (HPF, 10 mM), and stimulated with ATL-1 (10 nM) or PMA (10 ng/mL), a known NADPHox inducer, as a positive control. Cells that remained unstimulated were considered the control group. ROS production was assessed as described before. 26 The area under the curve is expressed as the mean 6 standard deviation (SD).
MV3 apoptosis
MV3 apoptosis was assessed via cell cycle analysis by flow cytometry. MV3 cells were distributed into 24-well plates at a density of 5 3 10 5 cells/well in 10% FBS medium. MU and TAM (1 3 10 6 cells/mL) were cultured in inserts (0.4 mm) of transwell plates and the TAM incubated for 15 min with or without DPI (10 mM), aminoguanidine (AG, 50 mM), or PEG-catalase (30 U/mL), followed by treatment with ATL-1 (10 nM) for 15 min. The analog and inhibitors were then removed, and TAM were co-cultured with MV3 cells for 72 hr. MV3cells treated with cycloheximide (5 mM) was used as the positive control. Thereafter, the MV3 cells were detached with 5 mM EDTA in HBSS. DNA fragmentation was accessed by propidium iodide (PI) staining (50 mg/mL PI; 0.1 mg/mL RNase A; 0.05% Triton X-100) and analyzed by flow cytometry with Accuri C6 V R (Becton Dickinson), as previously described. 27 Graphics show DNA fragmentation represented by the amount of hypodiploid cells in the sub G0/G1 phase of the cell cycle.
Preparation of cell extracts
MU and TAM (1 3 10 6 /mL) were incubated with different concentrations of ATL-1 (1-100 nM) and then frozen in an ice bath to stop the reaction. To obtain whole cell extracts, cells were resuspended in lysis buffer as previously described. 20 The total protein contents of the cell extracts were determined by the Bradford method. 28 
Immunoblotting
The membranes were blocked with 5% BSA in Tris-buffered saline (TBS) containing 0.1% Tween-20, and then probed with anti-iNOS (1:500), anti-ALX/FPR2, anti-arginase-1, antitubulin or anti-actin (1:1000) antibodies for 2 hr and developed as described previously. 20 Bands were visualized via an enhanced chemiluminescence system (ECL, Amersham, Arlington Heights, IL). In all instances, band density values were corrected by subtracting the background values.
Immunohistochemistry
Twenty-one days after administration of B16F10 cells, mice were killed, the tumor mass removed and immersed in the fixative solution for 24 hr. It was then embedded in optimum cutting temperature (O.C.T., Tissue-tek V R ) and sliced (10 lm) perpendicular to the tumor base (apical-basal axis) and stained with H&E. Sections were hydrated and the slides washed in TBS with 0.05% Tween 20 (T-PBS, SigmaAldrich), blocked with block solution (BSA 5% in T-TBS), and immunostained with antibodies to endothelial cells (CD105), MU (F480) and TAM (MRC1), used at a 1/100 dilution in PBS/Tween buffer overnight at 48C. Immunofluorescent images were developed with antibodies conjugated with fluorescein or phycoerythrin and counterstained with DAPI for nuclear staining. An irrelevant isotype IgG was used as negative control. 
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Statistical analysis
The data are representative of different experiments and expressed as the mean 6 S.D. The means from different treatments were compared by Student s t test and ANOVA, followed by the Bonferroni t test for unpaired values. Statistical significance was set at p < 0.05.
Results
Characterization of a TAM phenotype induced by a simulated tumor microenvironment in vitro Characteristic TAM markers are the macrophage mannose receptor (MRC1), and CD163, which are usually expressed on cell membranes of certain M2 subsets. 5, 27 For induction of a TAM-like phenotype by a simulated tumor microenvironment in vitro, MU derived by culture of peripheral blood monocytes were incubated with conditioned medium obtained from cultures of melanoma cells. MU were converted to a TAM profile expressing higher levels of MRC1 and CD163 than did untreated MU (Figs. 1a and 1b) .
One key feature of TAM is the high level of expression of IL-10, an immunosuppressive cytokine produced by TAM that allows these cells to assume the various functions of different M2 subsets. 2 Indeed, under our experimental conditions, the induced TAM presented high levels of IL-10 mRNA (Fig. 1c) . 6 cells) were treated with ATL-1 (10 nM) for 24 hr. IL-10 release was assessed by ELISA using an anti-IL-10 antibody. The results are expressed as the mean 6 SD of five independent experiments. *p < 0.05 when compared to TAM alone. (c) MU and TAM (1 3 10 6 cells) were incubated with or without ATL-1 (10 nM), 15-epi-LXA 4 (10 nM), LXA 4 (10 nM) and in the latter case, with M1 stimulus (LPS1mg/ mL 1 IFNg100ng/mL) for 72 hr. MRC1 expression was assessed by flow cytometry using the antibody anti-MRC1-PE. The results are expressed as the mean 6 S.D of three independent experiments. *p < 0.05 when compared to control MU; **p < 0.05 when compared to TAM. (d) MU (1 3 10 6 cells) were incubated with medium alone, MV3 conditioned medium (TAM), M1 stimulus (LPS1 mg/mL 1 IFNg 100 ng/mL), M2 stimuli: IL-4 (40 ng/mL), TGF-b (10 ng/mL), or VEGF (10 ng/mL) for 3 days. After washing cells were then incubated in the presence or absence of ATL-1 (10 nM) for 72 hr. MRC1 expression was assessed by flow cytometry using the anti-MRC1-PE antibody. The results are expressed as the mean 6 SE of three independent experiments. *p < 0.05 when compared to control MU; **p < 0.05 when compared to TAM. # p < 0.05 when compared to M1.
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LX and their analogs exert their regulatory activities via activation of the ALX receptor, a GPCR expressed in a variety of cellular types. 18 We demonstrated that TAM express ALX and the treatment of the cells with ATL-1 (10 nM) did not change this expression (Fig. 1d) . Furthermore, in the presence of ATL-1, the cells maintained viability even after 48 hr of incubation, as demonstrated by MTT assays (Fig. 1e) .
ATL-1 selectively decreases the mannose receptor M2 marker expression by TAM
To investigate the effects of ATL-1 on the TAM phenotype, we treated the cells with the analog for 72 hr. As demonstrated in Figure 2a , ATL-1 treatment decreased MRC1 expression to levels similar to those observed in MU. Furthermore, ATL-1 inhibited IL-10 release by TAM (Fig.  2b) . Importantly, the natural lipoxin, LXA 4 and its aspirininduced analogue, 15-epi-LXA 4 , induced similar effects to ATL-1 (Fig. 2c) . In striking contrast, ATL-1 had no effect on the M2 MRC1 phenotype induced by other M2 stimuli, such as IL-4, TGF-b and VEGF, and even induced an M2 profile in M1 cells previously treated with LPS (Fig. 2d) . These results suggest that TAM might represent a subset of M2 macrophages, which are selectively down-modulated by ATL-1 to an M1-like profile in vitro. A further response of TAM was the significant reversal of MRC1 expression by an M1 stimulus (Fig. 2c) . /mL) were cultured in 96-well plates, pretreated with BOC-1 (10 mM), and treated with ATL-1 (1-100 nM) for 8 hr. NO production was assessed by the Griess Reaction and analyzed on an EnvisionV R plate reader, as described in the Methods. *p < 0.05 when compared with TAM alone. **p < 0.05 when compared with TAM treated with ATL-1.
ATL-1 induces NO production by increasing the iNOS/arginase-1 ratio in TAM
In the tumor microenvironment, TAM, in contrast to M1 cells, exhibit deficient production of NO due to inhibition of iNOS activity by elevated levels of arginase-1. 8, 9, 30, 31 Figure 3b shows, in accord with those observations, that the TAM induced in the present study express high levels of arginase-1. Treatment of TAM with ATL-1 decreased arginase-1 and enhanced iNOS expression, thus increasing the iNOS/arginase-1 ratio (Figs. 3a-3c ). In accord with these results, ATL-1(10 nM) induced significant NO production by TAM, an effect that was inhibited by BOC-1, a selective inhibitor of ALX/FPR2 (Fig. 3d) .
ATL-1 induces ROS production by TAM
In addition to their limited ability to produce NO, 8, 9 TAM also produce low amounts of ROS (Figs. 4a and 4b ). After treatment with ATL-1 (10 nM), TAM generated significantly larger amounts of ROS, an effect impaired by both BOC-1 and DPI, an NADPH oxidase inhibitor (Figs. 4a and 4b) . Furthermore, ATL-1 had no effect on ROS production by MU. Additionally, we show that ATL-1, as a possible consequence of an increased production of ROS and NO, 31 induces peroxynitrite formation, an effect also inhibited by BOC-1 (Fig. 4c) .
ATL-1 induces MV3 apoptosis in a ROS-and NO-dependent manner
Since the activation of NO and ROS could lead to the recovery of the cytotoxic properties of TAM, 2 we analyzed the melanoma cell cycle after 72 h of co-incubation with TAM previously treated with ATL-1. Compared to MU-co-cultured tumor cells, MV3 melanoma cells co-cultured with TAM were protected from apoptosis (Fig. 5a) . By contrast, the treatment of TAM with ATL-1 (10 nM) reversed this antiapoptotic activity of TAM on MV3 to levels comparable to those seen with MU and with an M1 stimulus (Fig. 5a ). The incubation of tumor cells with supernatant from the ATL-1-treated TAM culture did not interfere with MV3 apoptosis (Fig. 5a) , suggesting that the pro-apoptotic effect depends on the presence of the TAM.
To investigate the contribution of the NADPH oxidasederived ROS to the pro-apoptotic effects of ATL-1-treated TAM, these cells were pretreated with DPI (10 lM) before incubation with the analog (10 nM). DPI impaired ATL-1-induced MV3 apoptosis, indicating that the analog induces tumor cell death via activation of the NADPH oxidase system in TAM (Fig. 5b) .
A simultaneous increase in the production of superoxide/ H 2 O 2 and NO could be lead to the potent cytotoxic (10 mM) ; or (c) aminoguanidine (AG, 50 mM) and polyethyleneglycol-catalase (PEG-Cat) (30 U/mL), followed by treatment with ATL-1 (10 nM) for 15 min. The analog and inhibitors were then removed, and the cells co-cultured with MV3 cells 72 hr. MV3 apoptosis was assessed by cell cycle analysis via flow cytometry. The results are expressed as the mean 6 SD of three independent experiments. *p < 0.05 when compared to MU; **p < 0.05 when compared to TAM; #p < 0.05 when compared to TAM plus ATL-1.
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properties displayed by ATL-1-stimulated TAM. To test this hypothesis, TAM were treated with aminoguanidine (AG, 50 mM) and PEG-catalase (30 U/mL), inhibitors of iNOS and H 2 O 2 , respectively, followed by the treatment with ATL-1 (10 nM). Treatment with the inhibitors completely blocked the pro-apoptotic effects of ATL-1, but did not potentiate the inhibitory effect of either one alone, suggesting that NO and H 2 O 2 could be converging to a common substrate (Fig. 5c ).
ATL-1 inhibits tumor progression in vivo
In view of these in vitro results, we investigated the effects of ATL-1 on tumor progression in a murine model in vivo. We observed that treatment with a unique dose of ATL-1 at the 
Discussion
The relationship between the infiltration of tumors by heterogeneous populations of myeloid cells and progression of the cancer has been widely investigated. In spite of the strong evidence for their ability to induce differentiation of MU to the general M2 phenotype bearing surface markers such as MRC-1 (mannose receptor), reports on the effects of lipoxins on tumor progression are limited. We first showed that incubation of M/ with conditioned medium from a human melanoma cell line culture provided a suitable TAM-like M/ model system to study lipoxin effects. In this study, we present novel and promising data on the distinct effects of ATL-1, a stable derivative of aspirin-induced LXA 4 on the behavior of these MU that present a TAM-like/M2 phenotype in the tumor microenvironment. A number of groups, including ours, have demonstrated that lipoxins and other proresolutive lipid mediators can induce M2 phenotypic markers in mononuclear cells. [19] [20] [21] Indeed, Li et al. screening the effects of lipoxins on na€ ıve and inflammatory monocytes and macrophages derived from the U937 cell line, demonstrated that LXA 4 induces the M2 phenotypes. 32 Vasconcelos et al. showed that lipoxins allowed in vivo the control of macrophage phenotypic profile, displaying a characteristic M2 phenotype. 33 Accordingly, we demonstrated that ATL-1 induces an M2 profile in human M1 cells, activated by LPS and IFNÇ, and maintains M2 polarization in M/-treated with IL4 -M(IL4)-a classical M2 stimulus. In contrast, we observed that the treatment with ATL-1 selectively alters TAM to an M1-like profile, increasing their potential tumoricidal activity and favoring control of tumor progression in vivo, a result replicated by the natural lipoxin LXA 4 and also by the aspirin-induced 15-epi-LXA 4 . These effects of ATL1 on tumor microenvironment seem to be macrophage intrinsic since ATL-1 have no effect on cancer cell proliferation and survival as already investigated before (data not shown). These effects emphasize a novel and important role of lipoxins in the modulation of the macrophage profile in the tumor microenvironment with consequent reduction of their protumor properties.
It is now recognized that M2 macrophages can be classified in different subsets depending upon the inducing signal, which has been recommended to be included in the M2 subset description. [5] [6] [7] 9 The TAM have been identified as a novel M2 subset, which can promote tumor growth, tissue remodeling, angiogenesis, and suppression of adaptive immunity. 3, 8 Thus, our demonstration that ATL-1 selectively alters the TAM/M2 profile to an M1-like phenotype, indicates an unforeseen specificity of the LX effect on TAM polarization.
In this study, we observed that ATL-1, besides decreasing the expression of the mannose receptor MRC1, a characteristic surface antigen marker of TAM, 29 also drastically inhibited IL-10 gene expression. IL-10, a known anti-inflammatory and immunosuppressive cytokine, reported to be present in the microenvironment of different tumors, inhibits the expression of pro-inflammatory mediators, including IL-12, inducible cyclooxygenase, and nitric oxide synthase, by phagocytic cells. 9, [34] [35] [36] This inhibitory effects of the ATL analog contrast clearly with other reports showing that lipoxins can induce IL-10 synthesis by macrophages in a non-tumor environment. 37 Furthermore, this inhibition of IL-10 expression by ATL-1 suggests that the alteration in macrophage profile could facilitate the restoration of their potent cytotoxic activities, thereby increasing NO and ROS production.
Indeed, we demonstrated that ATL-1, in changing the TAM phenotype, increases the production of NO and induces ROS generation by activating the NADPH oxidase system. These pro-oxidative effects triggered in TAM contrast, again, with those obtained in other M/ phenotypes, where inhibitory effects of lipoxins and other ALX/FPR2 agonists on reactive species production were demonstrated. [38] [39] [40] Corroborating the hypothesis of a selective effect of ATL-1 on TAM, we demonstrated that it had no effect on ROS production by peripheral blood-derived M/s. The NO production is consequence of a balance between iNOS and arginase-1 activity. 11 The arginase pathway limits arginine availability for iNOS action and NO synthesis. Interestingly, NO production by TAM triggered by ATL-1 seems to be more closely related to a decline in arginase-1 expression than to an augmentation in iNOS expression, resulting in an increase in the iNOS/ arginase-1 ratio.
Several studies have demonstrated that malignant cells are able to grow indefinitely because of unregulated proliferative capacity and acquired resistance to apoptosis, allowing these cells to become invasive and metastatic. 41, 42 Alterations in the TAM profile and the recovery of the cytotoxic properties of M/s have been proposed as part of an efficient strategy to control tumor progression. 11 Our data indicate that ATL-1, by triggering ROS and NO production, enables TAM to induce apoptosis of MV3 melanoma cells. Inhibition of either NADPH oxidase or iNOS systems alone impaired the proapoptotic effect of ATL-1-stimulated TAM on the tumor cells, suggesting a common intermediate which is responsible by the cytotoxic effects. An increased production of superoxide/H 2 O 2 and NO can lead to the production of the highly cytotoxic mediator peroxynitrite. 31 This is consistent with our observation that ATL-1 induces peroxynitrite production by TAM. Conceivably this metabolite could be the main factor responsible for the potent cytotoxic properties displayed by ATL-1-stimulated TAM.
Tumor cells need to avoid apoptosis, which is also induced by limited supplies of oxygen, nutrients, and growth factors. 43 ATL-1, in addition to its ability to alter TAM to a tumor pro-apoptotic phenotype, also inhibited human endothelial cell tubulogenesis stimulated by TAM in vitro (Supplemental Figure S1) . Furthermore, the treatment with ATL-1 decreased angiogenic markers in the tumor microenvironment, in vivo. The data corroborate early studies that suggested ATL-1 as a potent inhibitor of angiogenesis by down-regulating VEGFR activation, and inhibiting migration and proliferation of endothelial cells. 44, 45 Taken together, our data support the idea that the shift in macrophage profile can also contribute to the anti-angiogenic effects of ATL-1 in vivo.
The production of ATL by aspirin in vivo results from the inhibition of COX-2 through its acetylation. 16 Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, were reported to impair tumor progression through the suppression of proliferation, the induction of apoptosis, and the inhibition of the invasiveness of neoplastic cells. 46, 47 Interestingly, Claria et al. showed that ATL was produced by aspirinactivated neutrophils co-cultured with tumor cells, 48 and
proposed that lipoxins may have a function in the control of cancer by affecting leukocyte activity. Corroborating this suggestion, we demonstrate for the first time that lipoxins, by inducing a shift from the TAM/M2-like to the M1-like profile, promote inhibitory effects on tumor cell proliferation and survival, leading to tumor cell apoptosis and control of tumor progression in vivo. This work highlights an important role for lipoxins in tumor progression and suggests that these lipid mediators may become new targets for reducing the development and progression of cancer.
